



Stem cells and cell therapies in cardiology

Sergei V Jargin

Department of Pathology, Peoples' Friendship University of Russia, Moscow, Russia

Abstract

Last time, a large number of publications on stem cells (SC) and cell therapies have emerged. Discussed topics include the differentiation of exogenous SC into various cell lineages, replacement of senescent, dysfunctional and damaged cells. Some studies claimed that transplanted SC regenerate infarcted rodent hearts. This work was translated to the clinic. However, efficacy in human studies has been nil or ambiguous. It has become clear that exogenous cells were not forming new cardiac tissue. The action mode of SC remains incompletely described; alternative mechanisms have been proposed: immunomodulating, paracrine and anti-aging. However, there are no reasons to assume that special functions would be more developed in SC than in differentiated cells. Allogeneic transplantations carry the risk of infections and immunologic adverse events. In conclusion, SC are a promising field of research. Studies of more differentiated cells and cell-free products mimicking paracrine effects of cell-based therapies are promising as well. Therapeutic methods with unproven effects should be tested within the framework of high quality research shielded from the funding bias.

Keywords: stem cells, allogeneic transplantation, myocardial infarction, heart failure, cardiomyopathy

Introduction

Last time, a large number of publications on stem cells (SC) and cell therapies have emerged, some of them applying such terms as rejuvenation, anti-aging strategy etc.^[1-3] Discussed topics include the differentiation of exogenous SC into various cell lineages, replacement of senescent, dysfunctional and damaged cells. Remarkably, assumptions that SC can differentiate into specialized cellular elements have not been confirmed for such a perfect SC as the fertilized ovum. In the "experiment" performed by the nature - extrauterine pregnancy - no differentiation of pluripotent embryonic cells towards surrounding tissues is observed but an embryo and germinal layers are formed. The implantation of embryonic SC can result in a development of teratoma^[4,5]. It is known from general pathology that a focal cell proliferation results in the formation of a nodule rather than migration of individual cells into surrounding tissues. For a pathologist, it is difficult to envisage how SC migrate in tissues such as myocardium, liver or cartilage, arrive at places where they are supposed to be needed, and engraft in preexisting structures^[6,7].

Overall, SC-based therapies of cardiopulmonary diseases are still at their preliminary stage^[8]. The poor engraftment and survival of implanted cells is a recognized challenge^[9,10]. Since the early 2000s, several studies claimed that transplants of bone-marrow or other SC can regenerate the infarcted rodent heart. This work was translated to the clinic. However, efficacy in human studies has been nil or ambiguous. It has become clear that donor cells were not forming new cardiac tissue^[11]. As for the adipose-derived cell therapy with cardiac or systemic administration, there have been adverse events and no clear clinical evidence for the efficacy^[12]. The action mode of SC, if any, remains

incompletely described; alternative mechanisms have been proposed: immunomodulating, paracrine (anti-inflammatory, anti-apoptotic, anti-fibrotic, angiogenic, mitogenic), activation of precursor cells in the microenvironment etc^[3, 13-15] It was hypothesized that SC secrete anti-aging substances^[16]. However, there are no prima facie reasons to assume that special functions would be more developed in morphologically primitive SC or partly differentiated progenitors than in more differentiated cells. Note that the biological mission of SC is mitosis rather than secretion of specific cytokines. In any case, experiments with mature cells or cell-free products would be less expensive. The cell-free substances mimicking paracrine effects of cell-based therapies can be obtained e.g. from cell culture media. The latter approach would achieve a better dose standardizing than cell implantations whatever is understood by it^[17].

Allogeneic transplantations carry the risk of infections and immunologic adverse events^[18]. Among others, this is a matter of concern when cell therapies are applied for the treatment of diseases with participation of immune mechanisms in the pathogenesis such as cardiomyopathy. In cardiology, routes of SC "implantation" include transvenous, transendocardial, intracoronary and transepical injections^[19, 20-22]. In this connection, sources of the cell material for intracoronary injections e.g. abortion specimens and its purification from immunogenic components are of importance^[20]. The infusion of autologous bone marrow cells or fractions of the patient's own blood is sometimes named auto transplantation; it is associated with a lower risk than the all transplantation. However, benefits from such procedures are questionable apart from a restoration of the pool of hemopoietic cells after cytotoxic or

immunosuppressive treatments (e.g. of hematological malignancies or multiple sclerosis) that have been applied long since. Numerous cell therapies have been patented; just one recent example: cells collected from human placentas and umbilical cords were injected into acupuncture points as a “method of treatment of ischemic angiopathy of lower extremity vessels” [23].

Conclusion

All said, SC are a promising field of research. Studies of differentiated cells and cell-free products mimicking paracrine effects of cell-based therapies are promising as well. Cell therapies with scant evidence of efficacy should not be applied in human heart diseases [11]. Continuing to pour money into ineffective forms of cell therapy diverts funding from approaches that merit further investigation [11]. Some patients pay for cell therapies; but the valuable experience is partly lost for the science because conflicted researchers tend to overestimate positive results (if there are any) leaving adverse effects out of attention. One of the objections to prohibitive measures [24, 25] is that the hope is taken from severely ill patients. Obviously, therapeutic methods with unproven effects must be tested within the framework of high quality research shielded from the funding bias. Patients participating in such research should be treated free of charge. As for animal experiments, they must be also performed by integer researchers not influenced by conflicts of interest. Low quality studies increase the risk of bias i.e. misrepresentation of reality [12]. The deception is objectionable on the grounds that it limits autonomy and breaches trust; these grounds possibly do not apply to placebos when they are prescribed within appropriate ethical limits [26], although it can be problematic both on the professional and ethical levels [27]. In other words, placebo therapy with misinformation of a patient can be beneficial and ethically justifiable [28], but it is not a sufficient reason to publish biased information. In conclusion, the following statement should be agreed with: “...doubts will further raise the question if patients should spend their money for useless drug with no clear mechanism of action which shows no or little evidence of its efficiency” [29].

References

1. Lau A, Kennedy BK, Kirkland JL, Tullius SG. Mixing old and young: enhancing rejuvenation and accelerating aging. *J Clin Invest*, 2019; 129:4-11.
2. Nguyen N, Sussman MA. Rejuvenating the senescent heart. *Curr Opin Cardiol*, 2015; 30:235-239.
3. Neves J, Sousa-Victor P, Jasper H. Rejuvenating strategies for stem cell-based therapies in aging. *Cell Stem Cell*, 2017; 20:161-175.
4. Blum B, Benvenisty N. The tumorigenicity of diploid and aneuploid human pluripotent stem cells. *Cell Cycle* 2009; 8: 3822-3830.
5. Lin FC, Chen WP, Chu PH, Shyu KG, Wen MS. Current status and perspectives in stem cell therapy for heart. *Acta Cardiol Sin*, 2014; 30:382-394.
6. Jargin SV. Stem cells and cell therapy. *Cardiology*, 2010; 117:198.
7. Jargin SV. Stem cells and cell therapy: on the eve of scientific discovery. *Cell Tissue Biol*, 2011; 5:103-105.
8. Bardelli S, Moccetti M. Stem and progenitor cells in human cardiopulmonary development and regeneration. *Stem Cells Int*, 2017; 2017:2653142.
9. Tang JN, Cores J, Huang K, Cui XL, Luo L, *et al.* Concise Review: Is Cardiac Cell Therapy Dead? Embarrassing Trial Outcomes and New Directions for the Future. *Stem Cells Transl Med*, 2018; 7: 354-359.
10. Yanamandala M, Zhu W, Garry DJ, Kamp TJ, Hare JM, Jun HW, Yoon YS, Bursac N, Prabhu SD, Dorn GW 2nd, Bolli R, Kitsis RN, Zhang J. Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering. *J Am Coll Cardiol*, 2017; 70(6):766-775.
11. Editorial. A futile cycle in cell therapy. Should a cell therapy for heart disease with scant evidence of efficacy continue to be tested in humans? *Nat Biotechnol*, 2017; 35(4): 291.
12. Toyserkani NM, Jørgensen MG, Tabatabaeifar S, Jensen CH, Sheikh SP, Sørensen JA. Concise review: a safety assessment of adipose-derived cell therapy in clinical trials: a systematic review of reported adverse events. *Stem Cells Transl Med*, 2017; 6(9):1786-1794.
13. Comella K, Parcero J, Bansal H, Perez J, Lopez J, Agrawal A, Ichim T. Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy. *J Transl Med*, 2016; 14:158.
14. van den Akker F, de Jager SC, Sluijter JP. Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors. *Mediators Inflamm*, 2013; 2013: 181020.
15. Jeong H, Yim HW, Park HJ, Cho Y, Hong H, Kim NJ, Oh IH. Mesenchymal stem cell therapy for ischemic heart disease: systematic review and meta-analysis. *Int J Stem Cells*, 2018; 11:1-12.
16. Ullah M, Sun Z. Stem cells and anti-aging genes: double-edged sword-do the same job of life extension. *Stem Cell Res Ther*, 2018; 9:3.
17. Terzic A, Behfar A. Posology for regenerative therapy. *Circ Res*, 2017; 121:1213-1215.
18. Tasso R, Pennesi G. When stem cells meet immunoregulation. *Int Immunopharmacol*, 2009; 9:596-598.
19. Suncion VY, Ghersin E, Fishman JE, Zambrano JP, Karantalis V, Mandel N, *et al.* Does transcatheter injection of mesenchymal stem cells improve myocardial function locally or globally? An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. *Circ Res*, 2014; 114:1292-1301.
20. Kirillov AM, Fatkhudinov TKh, Dyachkov AV, Koroteev AV, Goldshtein DV, Bochkov NP. Transplantation of allogenic cells in the therapy of patients with dilated cardiomyopathy. *Bull Exp Biol Med*, 2007; 144:635-639.
21. Schoenhard JA, Hatzopoulos AK. Stem cell therapy: pieces of the puzzle. *J Cardiovasc Transl Res*, 2010; 3: 49-60.
22. Bilgimol JC, Ragupathi S, Vengadassalopathy L, Senthil NS, Selvakumar K, Ganesan M, Manjunath SR. Stem cells: An eventual treatment option for heart diseases. *World J Stem Cells*, 2015; 7:1118-1126.
23. Shomina EA, Yarygin NV, Yarygin KN. Method of treatment of ischemic angiopathy of lower extremity vessels. Patent of Russian Federation RU2649498C1; 2018.

24. Rossbauer M. Unproven stem-cell therapy ban. *Nature*, 2008; 454: 923.
25. Qiu J. China clamps down on controversial therapies. *Lancet*, 2009; 373:1834-1835.
26. Foddy B. A duty to deceive: placebos in clinical practice. *Am J Bioeth*, 2009; 9:4-12.
27. Hróbjartsson A. Clinical placebo interventions are unethical, unnecessary, and unprofessional. *J Clin Ethics*, 2008; 19: 66-69.
28. Linde K, Fässler M, Meissner K. Placebo interventions, placebo effects and clinical practice. *Philos Trans R Soc Lond B Biol Sci*, 2011; 366:1905-1912.
29. Stelmakh A, Abrahamovych O, Cherkas A. Highly purified calf hemodialysate (Actovegin®) may improve endothelial function by activation of proteasomes: A hypothesis explaining the possible mechanisms of action. *Med Hypotheses*, 2016; 95:77-81.